SBIR/STTR Research Award

STTR Phase II: Living Pharmacy for Diabetes and Obesity Treatment

Award identifier b0f83a27d03b2a0a92b48369caecfe377cb50ec12593faf37a40aef6adb1af66Awarding agency National Science Foundation

Award amount

$1,000,000

Program and phase

STTR · Phase II

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Simmbion LLC
Proposal award date
2025-03-12
Contract end date
2027-02-28
UEI
CDSMRMMK4ET3
Solicitation number
NSF 23-516
Topic code
BT

Research abstract

The broader impacts of this Small Business Technology Transfer (STTR) Phase II project could be both substantial and multifaceted, with far-reaching implications across the entire spectrum of healthcare, education, and environmental stewardship. This living pharmacy approach is an innovative and transformative cellular factory method of administering treatments and managing chronic diseases by maintaining steady-state drug levels over long periods of time without the need for frequent dosing. By synthesizing treatments directly within the body and replacing daily, weekly, or monthly dosing with a single dose, the technology has the potential to significantly enhance patient compliance, offering an alternative treatment modality that makes the disease invisible to daily life. Educationally, the proposed technology as a pioneering work may serve as a springboard for fostering innovation and research in the field of immuno-synthetic biology and biotechnology, paving the way for the next generation of scientists, researchers, and entrepreneurs to draw inspiration from nature’s design first. Scientifically, the platform could act as a testament to the exciting possibilities of symbiotic synthetic biology and the living pharmacy concept. This work spans the fields of immunology, microbiology, symbiotic biology, and synthetic biology, with potential dual applications in the defense industry and cancer prevention space. The proposed project aims to demonstrate the safety and tolerability of a novel and potentially harmless universal designer organism as a living pharmacy to treat diabetes and obesity in cats. Specifically, the plan is to demonstrate how a single injection can be effective for 12 weeks or longer to control blood glucose and weight gain for the companion animal market. This will serve as a model first, with the eventual goal of entering the human market. This cellular factory platform could facilitate a new era of cost-effective and patient-friendly treat

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $1,255,136. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.